HC Wainwright Forecasts Increased Earnings for Biomea Fusion

Biomea Fusion, Inc. (NASDAQ:BMEA) – Equities researchers at HC Wainwright upped their FY2026 EPS estimates for Biomea Fusion in a report issued on Wednesday, November 11th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.53) for the year, up from their prior estimate of ($0.65). HC Wainwright has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Biomea Fusion’s current full-year earnings is ($0.65) per share. HC Wainwright also issued estimates for Biomea Fusion’s Q4 2026 earnings at ($0.15) EPS, FY2027 earnings at ($0.60) EPS and FY2028 earnings at ($0.72) EPS.

Biomea Fusion (NASDAQ:BMEA) last released its earnings results on Tuesday, November 10th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.12.

Several other research firms have also commented on BMEA. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biomea Fusion in a research note on Monday, September 28th. Citigroup reissued a “market outperform” rating on shares of Biomea Fusion in a research note on Wednesday, September 30th. Citizens Jmp restated a “market outperform” rating and issued a $7.00 price target on shares of Biomea Fusion in a report on Wednesday, October 14th. Wall Street Zen downgraded shares of Biomea Fusion from a “hold” rating to a “sell” rating in a research note on Saturday, October 24th. Finally, Brookline Capital Markets started coverage on shares of Biomea Fusion in a report on Wednesday, October 7th. They set a “buy” rating on the stock. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Biomea Fusion has a consensus rating of “Moderate Buy” and an average price target of $7.60.

Biomea Fusion Stock Down 7.9%

Shares of Biomea Fusion stock opened at $0.56 on Friday. Biomea Fusion has a fifty-two week low of $0.54 and a fifty-two week high of $2.24. The business’s fifty day moving average is $1.16 and its two-hundred day moving average is $1.34. The firm has a market cap of $40.90 million, a PE ratio of -5.12 and a beta of -0.14.

Hedge Funds Weigh In On Biomea Fusion

A number of institutional investors and hedge funds have recently bought and sold shares of BMEA. Rathbones Group PLC acquired a new position in shares of Biomea Fusion during the first quarter worth $57,000. ADAR1 Capital Management LLC purchased a new stake in Biomea Fusion during the 2nd quarter worth $64,000. GSA Capital Partners LLP acquired a new position in Biomea Fusion in the 2nd quarter worth $318,000. BlackRock Inc. acquired a new position in Biomea Fusion in the 2nd quarter worth $1,052,000. Finally, Renaissance Technologies LLC lifted its holdings in Biomea Fusion by 174.3% in the 1st quarter. Renaissance Technologies LLC now owns 1,312,798 shares of the company’s stock worth $2,009,000 after buying an additional 834,179 shares in the last quarter. Hedge funds and other institutional investors own 96.72% of the company’s stock.

Biomea Fusion Company Profile

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for cancer and metabolic diseases. Its research uses a platform designed to create covalent inhibitors, which bind to specific protein targets. The company’s lead drug candidate, icovamenib (BMF-219), is an oral menin inhibitor being studied for potential use in conditions including certain blood cancers and type 2 diabetes. Biomea Fusion is based in Redwood City, California, and was founded in 2017.